These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19932057)

  • 1. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care.
    Stefanutti C; Vivenzio A; Di Giacomo S; Mazzarella B; Ferraro PM; Abbolito S
    Transfus Apher Sci; 2010 Feb; 42(1):21-6. PubMed ID: 19932057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study.
    Stefanutti C; D'Alessandri G; Russi G; De Silvestro G; Zenti MG; Marson P; Belotherkovsky D; Vivenzio A; Di Giacomo S
    Atheroscler Suppl; 2009 Dec; 10(5):89-94. PubMed ID: 20129383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
    Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
    Khan TZ; Pottle A; Pennell DJ; Barbir MS
    Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
    Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
    Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
    Heigl F; Hettich R; Mauch E; Klingel R; Fassbender C
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):50-54. PubMed ID: 28160245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.
    von Dryander M; Fischer S; Passauer J; Müller G; Bornstein SR; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):39-44. PubMed ID: 23357139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey.
    Stefanutti C; Morozzi C; Di Giacomo S;
    Ther Apher Dial; 2013 Apr; 17(2):169-78. PubMed ID: 23551673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?
    Mellwig KP; Horstkotte D; van Buuren F
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):18-21. PubMed ID: 28233270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
    Berent T; Derfler K; Berent R; Sinzinger H
    Atheroscler Suppl; 2019 Dec; 40():8-11. PubMed ID: 31818453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
    Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM
    Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
    Schampera S; Fischer S; Weiss N; Julius U
    Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):8-13. PubMed ID: 25672934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.